| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia ML Davila, I Riviere, X Wang, S Bartido, J Park, K Curran, SS Chung, ... Science translational medicine 6 (224), 224ra25-224ra25, 2014 | 2826 | 2014 |
| CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia RJ Brentjens, ML Davila, I Riviere, J Park, X Wang, LG Cowell, S Bartido, ... Science translational medicine 5 (177), 177ra38-177ra38, 2013 | 2417 | 2013 |
| Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia JH Park, I Rivière, M Gonen, X Wang, B Sénéchal, KJ Curran, C Sauter, ... New England Journal of Medicine 378 (5), 449-459, 2018 | 2377 | 2018 |
| Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias RJ Brentjens, I Rivière, JH Park, ML Davila, X Wang, J Stefanski, C Taylor, ... Blood, The Journal of the American Society of Hematology 118 (18), 4817-4828, 2011 | 1555 | 2011 |
| Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism MO Johnson, MM Wolf, MZ Madden, G Andrejeva, A Sugiura, ... Cell 175 (7), 1780-1795. e19, 2018 | 510 | 2018 |
| Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome V Staedtke, RY Bai, K Kim, M Darvas, ML Davila, GJ Riggins, ... Nature 564 (7735), 273-277, 2018 | 260 | 2018 |
| CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia ML Davila, CC Kloss, G Gunset, M Sadelain PloS one 8 (4), e61338, 2013 | 234 | 2013 |
| Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity A Ghosh, M Smith, SE James, ML Davila, E Velardi, KV Argyropoulos, ... Nature medicine 23 (2), 242-249, 2017 | 220 | 2017 |
| CAR models: next-generation CAR modifications for enhanced T-cell function D Abate-Daga, ML Davila Molecular Therapy-Oncolytics 3, 2016 | 209 | 2016 |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, ... Journal for immunotherapy of cancer 8 (2), 2020 | 185 | 2020 |
| Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ... Haematologica 106 (4), 978, 2021 | 179 | 2021 |
| Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma MD Jain, H Zhao, X Wang, R Atkins, M Menges, K Reid, K Spitler, ... Blood, The Journal of the American Society of Hematology 137 (19), 2621-2633, 2021 | 165 | 2021 |
| High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma EA Dean, RS Mhaskar, H Lu, MS Mousa, GS Krivenko, A Lazaryan, ... Blood Advances 4 (14), 3268-3276, 2020 | 161 | 2020 |
| How do CARs work? Early insights from recent clinical studies targeting CD19 ML Davila, R Brentjens, X Wang, I Rivière, M Sadelain Oncoimmunology 1 (9), 1577-1583, 2012 | 157 | 2012 |
| CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas M Gang, ND Marin, P Wong, CC Neal, L Marsala, M Foster, T Schappe, ... Blood, The Journal of the American Society of Hematology 136 (20), 2308-2318, 2020 | 154 | 2020 |
| CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia ML Davila, RJ Brentjens Clinical advances in hematology & oncology: H&O 14 (10), 802, 2016 | 142 | 2016 |
| Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies ML Davila, DCG Bouhassira, JH Park, KJ Curran, EL Smith, HJ Pegram, ... International journal of hematology 99, 361-371, 2014 | 133 | 2014 |
| Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma AJ Sim, MD Jain, NB Figura, JC Chavez, BD Shah, F Khimani, A Lazaryan, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 1012-1021, 2019 | 127 | 2019 |
| 4-1BB enhancement of CAR T function requires NF-κB and TRAFs G Li, JC Boucher, H Kotani, K Park, Y Zhang, B Shrestha, X Wang, L Guan, ... JCI insight 3 (18), 2018 | 124 | 2018 |
| Biology and clinical application of CAR T cells for B cell malignancies ML Davila, M Sadelain International journal of hematology 104, 6-17, 2016 | 118 | 2016 |
